• Norma Alejandra Rodriguez-Jimenez, Carlos E Garcia-Gonzalez, Karina Patricia Ayala-Lopez, Benjamin Trujillo-Hernandez, Erika Anita Aguilar-Chavez, Alberto Daniel Rocha-Muñoz, Jose Clemente Vasquez-Jimenez, Eva Olivas-Flores, Mario Salazar-Paramo, Esther Guadalupe Corona-Sanchez, Monica Vazquez-Del Mercado, Evangelina Varon-Villalpando, Adolfo Cota-Sanchez, Ernesto German Cardona-Muñoz, Jorge I Gamez-Nava, and Laura Gonzalez-Lopez.
• Programa de Doctorado en Farmacologia, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (U de G), Guadalajara, JAL, Mexico.
• Biomed Res Int. 2014 Jan 1; 2014: 510305.

ObjectiveTo compare the modifications in lipids between patients with rheumatoid arthritis (RA) receiving etanercept plus methotrexate (ETA + MTX) versus methotrexate (MTX) and their relationship with serum levels of tumor necrosis factor-alpha (TNF-α).MethodsIn an observational cohort study, we compared changes in lipid levels in patients receiving ETA + MTX versus MTX in RA. These groups were assessed at baseline and at 4 and 24 weeks, measuring clinical outcomes, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, and TNF-α.ResultsBaseline values for lipid levels were similar in both groups. HDL-C levels increased significantly only in the ETA + MTX group (from 45.5 to 50.0 mg/dL at 4 weeks, a 10.2% increase, P < 0.001, and to 56.0 mg/dL at 24 weeks, a 25.1% increase, P < 0.001), while other lipids underwent no significant changes. ETA + MTX also exhibited a significant increase in TNF-α (44.8 pg/mL at baseline versus 281.4 pg/mL at 24 weeks, P < 0.001). The MTX group had no significant changes in lipids or TNF-α. Significant differences in HDL-C between groups were observed at 24 weeks (P = 0.04) and also in TNF-α  (P = 0.01).ConclusionHDL-C levels increased significantly following treatment with ETA + MTX, without a relationship with decrease of TNF-α.

31 keywords...

hide…